Company Overview of Horizon Pharma plc
Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company offers ACTIMMUNE for reducing the frequency and severity of serious infections associated with chronic granulomatous disease; DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; PENNSAID for the treatment of pa...
1 Burlington Road
Founded in 2005
Key Executives for Horizon Pharma plc
Chairman, Chief Executive Officer and President
Total Annual Compensation: $982.3K
Chief Financial Officer and Executive Vice President of Finance
Total Annual Compensation: $210.9K
Chief Business Officer and Executive Vice President
Total Annual Compensation: $492.0K
Chief Medical Officer and Executive Vice President of Research & Development
Total Annual Compensation: $396.3K
Chief Commercial Officer and Executive Vice President
Total Annual Compensation: $194.5K
Compensation as of Fiscal Year 2014.
Horizon Pharma plc Key Developments
The U.S. Patent And Trademark Office Issues Additional Notice Of Allowance With Claims Covering PENNSAID(r)
Sep 2 15
Horizon Pharma plc announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/705,606 (U.S. publication number 2015-0231262), entitled 'Diclofenac Topical Formulation' that covers Horizon's U.S. approved product PENNSAID(r) (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire October 17, 2027. After issuance, Horizon plans to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
Horizon Pharma plc Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-17-2015 05:15 PM
Aug 14 15
Horizon Pharma plc Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-17-2015 05:15 PM. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States. Speakers: Timothy P. Walbert, Chairman, Chief Executive Officer and President.
Horizon Pharma plc Names George Hampton as Executive Vice President, Global Orphan Business Unit and International Operations
Aug 7 15
Horizon Pharma plc named George Hampton as executive vice president, global orphan business unit and international operations, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately. Hampton has also joined the Horizon's Executive Committee. Hampton joined Horizon Pharma in 2008 as a consultant and full time as a group vice president, international operations in April 2015. Most recently, Hampton served as president and chief executive officer of a privately held technology company.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|